The FDA granted accelerated approval to Loxo Oncology and Bayer’s larotrectinib for patients with solid tumours that have neurotrophic receptor tyrosine kinase (NTRK) gene fusions. Larotrectinib is the first drug to be developed entirely for a tissue-agnostic cancer indication that doesn’t depend on where the cancer originated…

Para acessar a publicação na íntegra clique aqui

Fonte: NATURE REVIEWS | DRUG DISCOVERY VOLUME 18 | JANUARY 2019 | 7